StockData

Puma Biotechnology vs Syndax Pharmaceuticals

PBYI and SNDX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PBYI and SNDX compare

Syndax Pharmaceuticals is the larger company, worth 2.2 times as much as Puma Biotechnology ($822M against $369M).

Syndax Pharmaceuticals grew revenue faster over the last twelve months (160% versus −2.9% for Puma Biotechnology).

Puma Biotechnology keeps more of each dollar of sales as profit, with a net margin of 11.6% compared with −72.3% at Syndax Pharmaceuticals.

Puma Biotechnology scores higher on the StockData Score (14 against 3 for Syndax Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPBYISNDX
Size and price
Market cap$369M$822M
Share price$7.14$9.20
Change, 1 year46.0%−44.6%
Change, 5 years121%−44.2%
Beta (5Y)1.321.72
Employees179298
StockData Score
Total score14 (better)3
Valuation score2 (better)1
Growth score2 (better)1
Performance score5 (better)0
Health score5 (better)1
Dividend score00
Valuation
P/E13.7×–
P/S1.6× (better)2.8×
P/B2.7×–
EV/EBITDA6.9×–
P/FCF9.0×–
FCF yield11.2%–
Fair value$8.84–
Margin of safety19.2%–
Growth
Revenue growth (TTM)−2.9%160% (better)
Revenue growth, 5Y average0.29%158% (better)
Net income growth (TTM)−44.9%–
EPS growth (TTM)−46.9%–
Profitability
Gross margin74.8%–
Operating margin13.2% (better)−61.7%
Net margin11.6% (better)−72.3%
FCF margin17.8%–
Return on equity22.0% (better)−426%
Return on invested capital42.7%–
Financial health
Debt / equity0.00–
Net debt / EBITDA−2.12–
Interest coverage8.6× (better)−44660.0×
Current ratio2.914.69 (better)
Altman Z-score−2.90−2.30 (better)
Piotroski F-score8 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions74.9%121%
Held by insiders18.9%1.8%
Insider net buying, 12 months−$2.1M (better)−$2.9M
Short interest, % of float10.3%21.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.